Ovid Therapeutics Announces Two Oral Presentations at the 14th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT...
May 09 2018 - 7:01AM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological diseases, today announced that
Matthew During, M.D., DSc., founder, president and chief scientific
officer of Ovid Therapeutics, will give two oral presentations at
the 14th Eilat Conference on New Antiepileptic Drugs and Devices
(EILAT XIV), taking place in Madrid, Spain. The presentations will
describe new preclinical findings for TAK-935/OV935, an inhibitor
of the enzyme cholesterol 24-hydroxylase (CH24H), in a Phase 1b/2a
clinical trial for dEE and OV329, an inactivator of GABA
aminotransferase (GABA-AT), in preclinical development.
“This will be the first presentation of data for
OV329, a promising preclinical compound with the potential for
clinical development in several neurological disorders. Our initial
work with OV329 has focused on the treatment of infantile spasms
due to its ability to inhibit GABA-AT, a well validated target for
resistant epilepsy,” said Dr. During. “We are very excited about
the strengths of our epilepsy programs, which also include
TAK-935/OV935 in a Phase 1b/2a clinical trial for the treatment of
dEE. Epilepsy affects nearly 50 million people worldwide making it
a global health problem. People with poorly-controlled seizures are
at increased risk of cognitive issues, injuries, premature death,
and overall lower quality of life. There is an urgent need to
develop new treatments that provide significant clinical
benefit.”
Details of the oral presentations below:
Title: TAK-935 (OV935): a first-in-class
cholesterol 24-hydroxylase inhibitorSession: Drugs
in Development Session 2Date and Time: Monday, May
14, 2018, 3:50 p.m. CEST
Title: OV329: A new and highly potent
inactivator of γ-aminobutyric acid aminotransferase (GABA-AT)
Session: Drugs in Development Session
3Date and Time: Monday, May 14, 2018, 4:45 p.m.
CEST
ABOUT
TAK-935/OV935TAK-935/OV935, which is being co-developed by
Ovid Therapeutics and Takeda Pharmaceutical Company Limited, is
currently being investigated for the treatment of rare
developmental and epileptic encephalopathies in a Phase 1b/2a
clinical trial. TAK-935/OV935 is a potent, highly-selective,
first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase
(CH24H). It is believed that CH24H is involved in over-activation
of the glutamatergic pathway, which has been shown to play a role
in the initiation and spread of seizure activity. TAK-935/OV935 is
the only molecule with this mechanism of action in clinical
development. The U.S. Food and Drug Administration has granted
orphan drug designation for TAK-935/OV935 for the treatment of
Dravet syndrome and Lennox-Gastaut syndrome, both types of
developmental and epileptic encephalopathies.
ABOUT OV329OV329 is a
preclinical compound being developed by Ovid Therapeutics for
epilepsy and other neurologic disorders, as part of the company’s
epilepsy portfolio. OV329 functions by inactivating GABA
aminotransferase (GABA-AT), a key metabolic enzyme of the brain’s
major inhibitory neurotransmitter, GABA. By inhibiting the
metabolism of GABA, OV329 leads to increased intracellular
concentrations of GABA. Given that epilepsy is characterized by
excessive neuronal excitation, the enhanced release of GABA may
suppress this excitatory signaling and may reduce seizures. GABA-AT
is a well validated target for treatment-resistant epilepsy and has
applications in multiple seizure types such as refractory complex
partial seizures and infantile spasms.
About Ovid TherapeuticsOvid
Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical
company using its BoldMedicine™ approach to develop medicines that
transform the lives of people with rare neurological disorders.
Ovid has a broad pipeline of first-in-class medicines. The
company’s lead investigational medicine, OV101, is currently in
development for the treatment of Angelman syndrome and Fragile X
syndrome. Ovid is also developing TAK-935/OV935 in collaboration
with Takeda Pharmaceutical Company Limited for the treatment of
rare developmental and epileptic encephalopathies (dEE).
For more information on Ovid, please visit
http://www.ovidrx.com/.
Forward-Looking Statements This
press release includes certain disclosures that contain
“forward-looking statements,” including, without limitation,
statements regarding (i) progress, timing, scope and results of
clinical trials for Ovid’s product candidates, and (ii) the
potential clinical benefit of TAK-935/OV935 to treat patients with
dEE. You can identify forward-looking statements because they
contain words such as “will,” “believes” and “expects.”
Forward-looking statements are based on Ovid’s current expectations
and assumptions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that may differ materially from those
contemplated by the forward-looking statements, which are neither
statements of historical fact nor guarantees or assurances of
future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements are set forth in Ovid’s filings with the Securities and
Exchange Commission, including its Quarterly Report on Form
10-Q for the period ended March 31, 2018 under the caption
“Risk Factors.” Ovid assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes
available.
ContactsInvestors: Ovid Therapeutics, Inc.Lora
PikeSenior Director, Investor Relations & Public
Relationslpike@ovidrx.com
Media: W2O GroupElliot Fox,
212-257-6724efox@w2ogroup.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Sep 2023 to Sep 2024